原发性肝癌肝移植135例  

Liver transplantation for hepatocellular carcinoma:an analysis of 135 cases

作　　者：肖朝辉[1] 张培瑞[1] 余灵祥[1] 常伟华[1] 胡雄伟[1] 孙颖哲[1] 李志伟[1] 

机构地区：[1]中国人民解放军第302医院肝胆外科,北京市100039

出　　处：《世界华人消化杂志》2011年第19期2072-2075,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨肝癌肝移植适应证、禁忌证、手术时机及术后肿瘤复发的防治.方法:对2005-04/2010-04连续实施的135例原发性肝癌患者进行随访和回顾性分析.结果:Milan标准组患者术后1、2年总体生存率分别为97.0%、89.5%,无瘤患者生存率分别为91.0%、71.6%;UCSF标准组患者术后1、2年总体生存率分别为95.1%、78.6%,无瘤患者生存率分别为90.2%、65.6%;超过UCSF标准组患者术后1年总体生存率为71.4%,无瘤患者1年总体生存率为57.1%.Milan、UCSF标准组生存率和无瘤生存率与超过UCSF标准组比较,差异有统计学意义(P<0.01).结论:肝移植是治疗肝癌的一个有效手段,术后应重视免疫抑制剂的应用调整,这对于防止肝癌术后复发有一定的意义.AIM：To investigate the indications,contraindications,operative timing,and prevention and management of recurrence for liver transplantation in patient with hepatocellular carcinoma （HCC）. METHODS：A retrospective analysis was performed of 135 consecutive HCC patients who underwent liver transplantation（LT）from April 2005 to April 2010 at our center.The outcome of patients meeting Milan or UCSF criteria and those beyond UCSF criteria was compared. RESULTS：There were no significant differences in 1-and 2-year survival rates and recurrencefree survival rate between patients meeting Milan criteria and those meeting UCSF criteria （97.0%vs 95.1%,89.5%vs 78.6%,91.0%vs 90.2%, 71.6%vs 65.6%;all P0.05）.The 1-year survival rate and recurrence-free survival rate for patients beyond-UCSF criteria were 71.4%and57.1%,respectively. CONCLUSION：Liver transplantation is an effective means of treating HCC.Attention should be paid to postoperative adjustment of immuno-suppressants to prevent tumor recurrence.

关 键 词：肝细胞癌 肝移植 复发 生存率 

分 类 号：R735.7[医药卫生—肿瘤]